Drugs / Adebrelimab
Trials 255 · started per year
today
1
3
2
9
4
8
21
103
64
40
20182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06735508 | Jan 2025 → Dec 2026 expected | non-small cell lung carcinoma | Guangdong Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06156267 | Jan 2024 → Apr 2026 overdue | pancreatic adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06685653 | ? → Nov 2026 expected | non-small cell lung carcinoma | Nanjing Tianyinshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT07063407 | Jul 2025 → Apr 2026 overdue | small cell lung carcinoma | Shanghai Hansoh Biomedical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07009457 | Jun 2025 → Sep 2027 expected | small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06902792 | Feb → Aug 2025 overdue | Langerhans cell histiocytosis | Second Affiliated Hospital of Wenzhou Medical University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06699576 | Dec 2024 → Dec 2026 expected | osteosarcoma, soft tissue sarcoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06594874 | Oct 2024 → Oct 2026 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06332170 | Apr 2024 → May 2026 overdue | neoplastic disease or syndrome | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06336707 | Apr 2024 → Apr 2026 overdue | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06225921 | Dec 2023 → Jan 2025 | esophageal squamous cell carcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT06181032 | Dec 2023 → Feb 2029 expected | biliary tract cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT05198817 | Feb 2022 → Jan 2023 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05082545 | Nov 2021 → Jul 2023 | cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05048134 | Oct 2021 → Feb 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04979390 | Aug 2021 → Feb 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03995472 | Feb 2020 → Jan 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04041011 | Sep 2019 → Apr 2021 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03474289 | Mar 2018 → Jan 2019 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03133247 | Jun 2017 → Apr 2019 | cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1/228 trials | ||||||
| Phase 1/2 | NCT07615283 | May 2026 → May 2030 expected | mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07595172 | Apr 2026 → Aug 2028 expected | pancreatic ductal adenocarcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07392541 | Jan 2026 → Jan 2028 expected | biliary tract cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07296341 | Jan 2026 → Oct 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07229586 | Dec 2025 → Dec 2027 expected | neoplasm | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07073534 | Jul 2025 → Dec 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07059221 | Jul 2025 → Mar 2027 expected | head and neck squamous cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06741020 | Mar 2025 → Jun 2026 overdue | hepatocellular carcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06597513 | Dec 2024 → Dec 2025 overdue | small cell lung carcinoma | Zhou Chengzhi | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06592287 | Sep 2024 → Sep 2025 overdue | gastric cancer | Xianglin Yuan | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06776770 | Aug 2024 → Sep 2026 expected | gastric cancer | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06385678 | Jul 2024 → Dec 2025 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06527898 | Jul 2024 → Jul 2026 overdue | small cell lung carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06474468 | Jun 2024 → Oct 2026 expected | esophageal cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06427239 | Jun 2024 → Jun 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06454448 | Jun 2024 → Jun 2025 overdue | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06439589 | Jun 2024 → Dec 2025 overdue | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06417554 | May 2024 → Jul 2027 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06373133 | May 2024 → Nov 2026 expected | colorectal cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06332950 | Apr 2024 → Apr 2027 expected | small cell lung carcinoma | Baohui Han | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06222879 | Feb 2024 → Oct 2026 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06092268 | Oct 2023 → Dec 2025 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05924997 | Jul 2023 → Jun 2025 | hepatocellular carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05794477 | Apr 2023 → Jul 2025 | neoplasm | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05765032 | Dec 2022 → Apr 2025 overdue | neoplasm | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05482568 | Sep 2022 → Dec 2026 expected | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04400188 | Jun 2020 → Jan 2022 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2174 trials | ||||||
| Phase 2 | NCT07684040 | Aug 2026 → Jul 2030 expected | liver cancer | Affiliated Hospital of Guangdong Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07704645 | Aug 2026 → Jun 2028 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07567326 | Jul 2026 → Dec 2028 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07638436 | Jun 2026 → Jan 2028 expected | esophageal squamous cell carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07584031 | Jun 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07624201 | Jun 2026 → Jun 2028 expected | urinary bladder carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07691593 | Jun 2026 → Oct 2027 expected | malignant pancreatic neoplasm | Changhai Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07687433 | May 2026 → May 2028 expected | rectal cancer | Harbin Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07595770 | May 2026 → Jan 2028 expected | esophageal squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07452601 | May 2026 → Feb 2027 expected | esophageal squamous cell carcinoma | Tang-Du Hospital | Recruiting | No outcome recorded |
| Show all 174 trials opens the full record — a long page | ||||||
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07454720 | Mar 2026 → Nov 2032 expected | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06879145 | Apr 2025 → Dec 2031 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06335355 | Mar 2024 → Oct 2028 expected | non-small cell lung carcinoma | Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT07691762 | Jul 2026 → Apr 2031 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07679360 | Jul 2026 → Dec 2030 expected | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07522151 | May 2026 → Dec 2029 expected | gastroesophageal cancer | Shanghai Shengdi Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07560358 | May 2026 → Dec 2029 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07464327 | Mar 2026 → Dec 2028 expected | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07393542 | Feb 2026 → Sep 2027 expected | urothelial carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07229625 | Jan 2026 → Dec 2029 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07238569 | Dec 2025 → Dec 2029 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07170995 | Oct 2025 → Dec 2030 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07168200 | Oct 2025 → Apr 2028 expected | cervical cancer | Shanghai Shengdi Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07111832 | Aug 2025 → Mar 2028 expected | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07118527 | Aug 2025 → Oct 2030 expected | gastroesophageal adenocarcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06913777 | Apr 2025 → Oct 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT04516681 | Dec 2024 → Dec 2025 overdue | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06672133 | Dec 2024 → Jun 2029 expected | small cell lung carcinoma | Jinming Yu | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06618664 | Oct 2024 → Sep 2026 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05496166 | Aug 2023 → Aug 2027 expected | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04691063 | Jan 2021 → May 2025 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04316364 | Jul 2020 → Apr 2023 overdue | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT03711305 | Dec 2018 → Oct 2022 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06417606 | May 2024 → Apr 2025 | intrahepatic cholangiocarcinoma | Zhiyong Huang | Unknown | No outcome recorded |
| Phase 4 | NCT06192186 | Dec 2023 → Dec 2025 | gastric adenocarcinoma | Yang Jianjun, PhD | Unknown | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07388095 | Feb 2026 → Feb 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06893887 | May 2025 → Mar 2027 expected | hepatocellular carcinoma | Nanjing Tianyinshan Hospital | Recruiting | No outcome recorded |
| — | NCT06853678 | Feb 2025 → Jul 2026 overdue | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT06480864 | Aug 2024 → Aug 2025 overdue | small cell lung carcinoma | Yunpeng Liu | Recruiting | No outcome recorded |
| — | NCT06613113 | Aug 2024 → Apr 2025 overdue | colorectal cancer | Ningbo Medical Center Lihuili Hospital | Recruiting | No outcome recorded |
| — | NCT06420908 | May 2024 → May 2026 | esophageal squamous cell carcinoma | Hebei Medical University Fourth Hospital | Withdrawn | No outcome recorded |
| — | NCT05132790 | Sep 2023 → Dec 2024 overdue | breast cancer | Shengjing Hospital | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 35 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06350006 Background | May 2024 → Dec 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05942378 Background | Jul 2023 → Sep 2025 | cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT07239596 Background | Jan 2026 → Dec 2030 expected | renal cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07105592 Background | May 2025 → May 2027 expected | head and neck squamous cell carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06840002 Background | Mar 2025 → May 2026 overdue | ovarian carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06703177 Background | Feb 2025 → Jan 2026 overdue | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06754930 Background | Feb 2025 → Dec 2027 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06639347 Background | Nov 2024 → May 2027 expected | urothelial carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06434103 Background | Oct 2024 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06512051 Background | Jul 2024 → Oct 2026 expected | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06474455 Background | Jul 2024 → Jun 2029 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06479473 Background | Jun 2024 → Mar 2025 overdue | small cell lung carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05416775 Background | Aug 2022 → Jun 2026 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05444088 Background | Aug 2022 → Jun 2026 | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07682272 Background | Jul 2026 → Jul 2027 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07241767 Background | Nov 2025 → Nov 2027 expected | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07131514 Background | Aug 2025 → Jun 2027 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07137858 Comparator | Aug 2025 → Jun 2027 expected | oral cavity squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07071714 Background | Jul 2025 → Oct 2031 expected | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06908668 Background | Mar 2025 → Sep 2028 expected | Her2-receptor negative breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06844474 Background | Mar 2025 → Aug 2026 overdue | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06739928 Background | Jan 2025 → Jun 2026 overdue | small cell lung carcinoma | Guangzhou Institute of Respiratory Disease | Recruiting | No outcome recorded |
| Phase 2 | NCT06610734 Background | Dec 2024 → Dec 2026 expected | small cell lung carcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06684158 Background | Nov 2024 → Mar 2027 expected | gastroesophageal junction adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06771609 Comparator | Sep 2024 → Sep 2028 expected | triple-negative breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06433609 Background | Aug 2024 → Mar 2027 expected | breast cancer | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06537505 Background | Aug 2024 → Apr 2027 expected | cancer | Beidahuang Industry Group General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06465563 Background | Jul 2024 → Dec 2026 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06247956 Background | Mar 2024 → Dec 2025 overdue | digestive system carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06165900 Background | Sep 2023 → Dec 2025 overdue | breast cancer | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06037655 Background | Sep 2023 → Mar 2026 overdue | biliary tract neoplasm | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06791460 Background | Mar 2025 → Feb 2028 expected | ovarian carcinoma | Obstetrics & Gynecology Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06675214 Background | Jul 2024 → Jul 2027 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06092957 Background | Oct 2023 → Oct 2029 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 291 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adebrelimab | “This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without...” NCT06775275 ↗254“Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous...” NCT06417606 ↗ “a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until...” NCT06675214 ↗ “This prospective, single-arm, multicenter clinical study aims to preliminarily evaluate the efficacy and safety of Trastuzumab Rezetecan combined with Adebrelimab as...” NCT07624201 ↗ “Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease...” NCT06613113 ↗ “Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic...” NCT07170995 ↗ “TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration).” NCT06908668 ↗ “We aimed to assess the efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with standard chemotherapy as a first-line treatment for ES-SCLC.” PMID 35576956 ↗ May 2022 “After 4 cycles of concurrent chemoradiotherapy, the non-progressing subjects will continue to receive adebrelimab (1200 mg, IV, Q3W) maintenance therapy.” NCT07559786 ↗ “Immunotherapy consolidation began at the third cycle of chemotherapy: Adebrelimab 1200mg q3w to 2 year or disease progression” NCT06527898 ↗ “This study marks the first application of Adebrelimab in pediatric patients with Langerhans Cell Histiocytosis (LCH).” NCT06902792 ↗ “albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg were administered intravenously.” NCT07137858 ↗ “SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles.” NCT05496166 ↗ “Participants in the experimental arm will receive intravenous infusions of HS-20093 and adebrelimab” NCT07464327 ↗ “Adebrelimab is a recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1.” NCT06455410 ↗ “Adebrelimab Injection，intravenous infusion, Day 1, every 3 weeks for 2 cycles.” NCT07584031 ↗ “PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.” NCT06702566 ↗ “Adebrelimab was given intravenously, 600mg each time, once every 2 weeks” NCT04215003 ↗ “Radiotherapy followed by Adebrelimab+Bevacizumab+Cisplatin/Carboplatin” NCT07638852 ↗ “a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg” NCT06092957 ↗ “Adebrelimab (1200 mg) every three weeks intravenously” NCT06037655 ↗ “Adebrelimab 1200mg day 1 q3w totally 4 to 6 cycles” NCT06479473 ↗ “Drug: Adebrelimab administered as an IV infusion” NCT05765032 ↗ “SHR-1316（Adebrelimab Injection）” NCT06237257 ↗ “Adebrelimab, 1200mg，q3w，2 year” NCT06943235 ↗ “adebrelimab: 1200 mg iv, q3w” NCT07560358 ↗ |
| Known as | ADE | “intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)” NCT06737913 ↗ |
| Known as | Adebrelimab Injection | “-Generic Name: Adebrelimab Injection -Trade name: Ariel -English name: Adebrelimab Injection” NCT06902792 ↗ |
| Known as | Ariel | “-Generic Name: Adebrelimab Injection -Trade name: Ariel -English name: Adebrelimab Injection” NCT06902792 ↗ |
| Known as | SHR-1316 | “The therapeutic aim of Adebrelimab (SHR-1316) is to inhibit tumor growth by specifically blocking the binding of PD-1 to PD-L1 and terminating the immunosuppressive signals...” NCT06405061 ↗45“A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative...” NCT07522151 ↗ “The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab (SHR-1316) and chemotherapy in...” NCT06178211 ↗ “Adebrelima(SHR-1316) is a recombinant humanized IgG4 antibody that binds efficiently and specifically to human and cynomolgus programmed cell death ligand 1 (PD-L1, CD274, or B7-H1)” NCT06375642 ↗ “Adebrelimab (SHR-1316) is a novel humanised IgG4 monoclonal antibody against PD-L1.” NCT07062328 ↗ “Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion” NCT06439589 ↗ “adebrelimab (SHR-1316), a novel anti-PD-L1 antibody” PMID 35576956 ↗ May 2022 “Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin” NCT06869213 ↗ “Drug: SHR-1316 given intravenously (IV).” NCT04041011 ↗ “SHR-1316（Adebrelimab Injection）” NCT06237257 ↗ |
| Action | Inhibit | “Anti-PD-L1 antibody” NCT04647357 ↗ |
| Modality | Monoclonal antibody | “SHR-1316 is a humanized IgG4 monoclonal antibody” NCT03133247 ↗ |
| Route | Intravenous | “SHR-1316 administrated intravenously(IV)” NCT03474289 ↗ |
| Target | CD274 | “binds efficiently and specifically to human and cynomolgus programmed cell death ligand 1 (PD-L1, CD274, or B7-H1)” NCT06375642 ↗ |